Nordea Investment Management AB Increases Stock Position in Align Technology, Inc. $ALGN

Nordea Investment Management AB grew its stake in shares of Align Technology, Inc. (NASDAQ:ALGN) by 94.5% during the second quarter, HoldingsChannel.com reports. The fund owned 638,341 shares of the medical equipment provider’s stock after buying an additional 310,091 shares during the quarter. Nordea Investment Management AB’s holdings in Align Technology were worth $121,055,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the stock. Praxis Investment Management Inc. boosted its holdings in shares of Align Technology by 41.4% during the 2nd quarter. Praxis Investment Management Inc. now owns 2,220 shares of the medical equipment provider’s stock valued at $420,000 after acquiring an additional 650 shares during the last quarter. Generali Asset Management SPA SGR boosted its holdings in shares of Align Technology by 30.1% during the 2nd quarter. Generali Asset Management SPA SGR now owns 10,764 shares of the medical equipment provider’s stock valued at $2,038,000 after acquiring an additional 2,488 shares during the last quarter. Twin Tree Management LP boosted its holdings in shares of Align Technology by 611.3% during the 2nd quarter. Twin Tree Management LP now owns 32,177 shares of the medical equipment provider’s stock valued at $6,092,000 after acquiring an additional 27,653 shares during the last quarter. Applied Fundamental Research LLC purchased a new stake in shares of Align Technology during the 2nd quarter valued at about $5,925,000. Finally, Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Align Technology by 4.5% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 2,372 shares of the medical equipment provider’s stock valued at $449,000 after acquiring an additional 102 shares during the last quarter. Hedge funds and other institutional investors own 88.43% of the company’s stock.

Align Technology Price Performance

Shares of ALGN opened at $130.45 on Friday. Align Technology, Inc. has a 1 year low of $122.00 and a 1 year high of $246.19. The company has a 50 day simple moving average of $134.71 and a two-hundred day simple moving average of $163.30. The firm has a market cap of $9.46 billion, a P/E ratio of 22.00, a price-to-earnings-growth ratio of 1.47 and a beta of 1.70.

Align Technology (NASDAQ:ALGN) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $2.49 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.08). Align Technology had a net margin of 11.04% and a return on equity of 13.36%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same period last year, the business earned $2.41 earnings per share. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. Align Technology has set its Q3 2025 guidance at EPS. On average, sell-side analysts anticipate that Align Technology, Inc. will post 7.98 earnings per share for the current year.

Align Technology announced that its Board of Directors has initiated a share repurchase plan on Tuesday, August 5th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Transactions at Align Technology

In related news, CEO Joseph M. Hogan acquired 7,576 shares of the business’s stock in a transaction on Friday, August 1st. The stock was acquired at an average cost of $131.49 per share, with a total value of $996,168.24. Following the acquisition, the chief executive officer directly owned 184,945 shares in the company, valued at $24,318,418.05. This represents a 4.27% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.66% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ALGN has been the topic of a number of recent analyst reports. Zacks Research raised shares of Align Technology from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 30th. Stifel Nicolaus lowered their price objective on shares of Align Technology from $275.00 to $200.00 and set a “buy” rating on the stock in a research note on Thursday, July 31st. Piper Sandler lowered their price objective on shares of Align Technology from $250.00 to $190.00 and set an “overweight” rating on the stock in a research note on Thursday, July 31st. Evercore ISI lowered their price objective on shares of Align Technology from $170.00 to $160.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 8th. Finally, Mizuho decreased their target price on shares of Align Technology from $210.00 to $170.00 and set an “outperform” rating on the stock in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $182.67.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.